167 related articles for article (PubMed ID: 16999715)
1. Safety of live-virus vaccines for children with immune deficiency.
Luthy KE; Tiedeman ME; Beckstrand RL; Mills DA
J Am Acad Nurse Pract; 2006 Oct; 18(10):494-503. PubMed ID: 16999715
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and safety of immunization with live-attenuated and inactivated vaccines for pediatric liver transplantation recipients.
Kawano Y; Suzuki M; Kawada J; Kimura H; Kamei H; Ohnishi Y; Ono Y; Uchida H; Ogura Y; Ito Y
Vaccine; 2015 Mar; 33(12):1440-5. PubMed ID: 25665961
[TBL] [Abstract][Full Text] [Related]
4. A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.
Reisinger KS; Brown ML; Xu J; Sullivan BJ; Marshall GS; Nauert B; Matson DO; Silas PE; Schödel F; Gress JO; Kuter BJ;
Pediatrics; 2006 Feb; 117(2):265-72. PubMed ID: 16452343
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of a second dose of measles-mumps-rubella-varicella vaccine in healthy children aged 5 to 6 years.
Vesikari T; Baer M; Willems P
Pediatr Infect Dis J; 2007 Feb; 26(2):153-8. PubMed ID: 17259879
[TBL] [Abstract][Full Text] [Related]
6. Effective and safe immunizations with live-attenuated vaccines for children after living donor liver transplantation.
Shinjoh M; Miyairi I; Hoshino K; Takahashi T; Nakayama T
Vaccine; 2008 Dec; 26(52):6859-63. PubMed ID: 18930096
[TBL] [Abstract][Full Text] [Related]
7. Safety and immunogenicity of a measles-mumps-rubella-varicella vaccine given as a second dose in children up to six years of age.
Halperin SA; Ferrera G; Scheifele D; Predy G; Stella G; Cuccia M; Douha M; Willems P
Vaccine; 2009 May; 27(20):2701-6. PubMed ID: 19428882
[TBL] [Abstract][Full Text] [Related]
8. Measles-mumps-rubella and varicella vaccine responses in extremely preterm infants.
D'Angio CT; Boohene PA; Mowrer A; Audet S; Menegus MA; Schmid DS; Beeler JA
Pediatrics; 2007 Mar; 119(3):e574-9. PubMed ID: 17332177
[TBL] [Abstract][Full Text] [Related]
9. Immunogenicity and safety of measles-mumps-rubella-varicella (MMRV) vaccine followed by one dose of varicella vaccine in children aged 15 months-2 years or 2-6 years primed with measles-mumps-rubella (MMR) vaccine.
Gillet Y; Steri GC; Behre U; Arsène JP; Lanse X; Helm K; Esposito S; Meister N; Desole MG; Douha M; Willems P
Vaccine; 2009 Jan; 27(3):446-53. PubMed ID: 19007835
[TBL] [Abstract][Full Text] [Related]
10. Live attenuated measles and mumps viral strain-containing vaccines and hearing loss: Vaccine Adverse Event Reporting System (VAERS), United States, 1990--2003.
Asatryan A; Pool V; Chen RT; Kohl KS; Davis RL; Iskander JK;
Vaccine; 2008 Feb; 26(9):1166-72. PubMed ID: 18255204
[TBL] [Abstract][Full Text] [Related]
11. Immunization in the adult immunocompromised host.
Löbermann M; Boršo D; Hilgendorf I; Fritzsche C; Zettl UK; Reisinger EC
Autoimmun Rev; 2012 Jan; 11(3):212-8. PubMed ID: 21621004
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of measles, mumps, rubella and varicella live viral vaccines in transplant recipients receiving immunosuppressive drugs.
Danerseau AM; Robinson JL
World J Pediatr; 2008 Nov; 4(4):254-8. PubMed ID: 19104888
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the safety and immunogenicity of a refrigerator-stable versus a frozen formulation of ProQuad (measles, mumps, rubella, and varicella virus vaccine live).
Bernstein HH; Eves K; Campbell K; Black SB; Twiggs JD; Reisinger KS; Conti RM; Flodmark CE; Rombo L; Klopfer S; Schödel F; Hartzel J; Kuter BJ;
Pediatrics; 2007 Jun; 119(6):e1299-305. PubMed ID: 17502347
[TBL] [Abstract][Full Text] [Related]
14. Risk of immune thrombocytopenic purpura after measles-mumps-rubella immunization in children.
France EK; Glanz J; Xu S; Hambidge S; Yamasaki K; Black SB; Marcy M; Mullooly JP; Jackson LA; Nordin J; Belongia EA; Hohman K; Chen RT; Davis R;
Pediatrics; 2008 Mar; 121(3):e687-92. PubMed ID: 18310189
[TBL] [Abstract][Full Text] [Related]
15. Safety and immunogenicity of early vaccination with two doses of tetravalent measles-mumps-rubella-varicella (MMRV) vaccine in healthy children from 9 months of age.
Goh P; Lim FS; Han HH; Willems P
Infection; 2007 Oct; 35(5):326-33. PubMed ID: 17710370
[TBL] [Abstract][Full Text] [Related]
16. Immunizations for pediatric transplant patients.
Gershon AA
Kidney Int Suppl; 1993 Oct; 43():S87-90. PubMed ID: 8246377
[TBL] [Abstract][Full Text] [Related]
17. Perspective on live varicella vaccine.
Gershon AA; Katz SL
J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
[TBL] [Abstract][Full Text] [Related]
18. Update on universal childhood immunizations.
Hamlin J; Senthilnathan S; Bernstein HH
Curr Opin Pediatr; 2008 Aug; 20(4):483-9. PubMed ID: 18622208
[TBL] [Abstract][Full Text] [Related]
19. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
[TBL] [Abstract][Full Text] [Related]
20. Immunization programs for infants, children, adolescents, and adults: clinical practice guidelines by the Infectious Diseases Society of America.
Pickering LK; Baker CJ; Freed GL; Gall SA; Grogg SE; Poland GA; Rodewald LE; Schaffner W; Stinchfield P; Tan L; Zimmerman RK; Orenstein WA;
Clin Infect Dis; 2009 Sep; 49(6):817-40. PubMed ID: 19659433
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
